A decrease in CSF Aβ42 is especially indicative of an amyloidogenic process, while an increase in tau proteins (total tau and its phosphorylated form p-tau (181)) is known to be associated with axonal loss and tau pathology in AD [9, 10]. This evidence concerns the gene MAPT and Alzheimer disease.